Association of the SLC6A3 Gene rs2652511 Polymorphism with Methamphetamine Abuse Disorder in the Iranian Population

Document Type : Original Article

Authors

1 Department of Cellular and Molecular Biology, Bonab Branch, Islamic Azad University, Bonab, Iran

2 Medicinal Plants Research Center, Maragheh University of Medical Sciences, Maragheh, Iran

10.34172/ahj.1484

Abstract

Background: Besides its physical and psychological effects on individuals, addiction is a major personal and societal issue that threatens cultural, political, and community well-being. Genetic factors play essential roles in susceptibility to methamphetamine dependence. The purpose of this study was to investigate the correlation between methamphetamine use disorder in Iranian males and the rs2652511 polymorphism in the promoter of SLC6A3.
Methods: We recruited 100 men with methamphetamine use disorder as cases and 100 age- and ethnically-matched normal men from East Azerbaijan, Tabriz, Iran as healthy controls. From peripheral blood leukocytes, genomic DNA was extracted. PCR-RFLP was utilized for genotyping.
Findings: The genotype distribution of rs2652511 polymorphism in the case group was 56% CC, 33% CT, and 11% 44, whereas in the control group it was 25% CC, 42% CT, and 33% TT. According to statistical analysis, there was a substantial variation in genotype and allele frequencies of the rs2652511 polymorphism between the case group and the healthy control group (P > 0.05).
Conclusion: Our research revealed that the rs2652511 polymorphism in the SLC6A3 gene was associated with methamphetamine misuse disorder in the Iranian population. To clarify the exact role of this polymorphism in the pathology of methamphetamine use disorder, further research is required across different racial and geographic groups.

Highlights

Hossein Soltanzadeh(google scholar)(pubmed)

Keywords

References

  1. Liu Y, Hao B, Shi Y, Xue L, Wang X, Chen Y, et al. Violent offences of methamphetamine users and dilemmas of forensic psychiatric assessment. Forensic Sci Res. 2017;2(1):11-7. doi: 10.1080/20961790.2017.1287155.
  2. Prakash MD, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V. Methamphetamine: effects on the brain, gut and immune system. Pharmacol Res. 2017;120:60-7. doi: 10.1016/j.phrs.2017.03.009.
  3. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115-26. doi: 10.1007/s40263-014-0209-8.
  4. Oruji F, Baghbani Arani F, Mahdavi Ortakand M. Evaluation of the gene expression of IL-1β and CASP-1 related to inflammation process in glomerulonephritis patients. J Anim Environ. 2018;10(3):477-82.
  5. Asadi Z, Hallajzadeh J, Fathi S, Khanbabaie G, Soltanzadeh H. Expression of microRNA-195 increased significantly in patients with methamphetamine abuse disorder. Gene Cell Tissue. 2021;9(2):e118755. doi: 10.5812/gct.118755.
  6. Fathi S, Soltanzadeh H, Tanomand A, Asadi Z, Rezai Moradali S. Investigation of miR-222 as a potential biomarker in diagnosis of patients with methamphetamine abuse disorder. Egypt J Med Hum Genet. 2022;23(1):67. doi: 10.1186/ s43042-022-00281-1.
  7. Soltanzadeh H, Hojjati Bonab Z. Investigation of MIRs in amphetamine misusers. J Shahid Sadoughi Univ Med Sci. 2024;32(4):7739-53. doi: 10.18502/ssu.v32i4.15837.
  8. Khanbabaie G, Soltanzadeh H, Montazem H. High expressions of microRNA-143 in patients with methamphetamine abuse disorder: case-control study. Res Mol Med. 2022;10(4):255- 62. doi: 10.32598/rmm.10.4.1263.1.
  9. Rezai Moradali S, Soltanzadeh H, Montazam H, Asadi Z, Fathi S. MicroRNA-127 and microRNA-132 expression in patients with methamphetamine abuse in East Azerbaijan, Iran: a case-control study. Addict Health. 2022;14(3):214-7. doi: 10.34172/ahj.2022.1298.
  10. Hashemi A, Bigdeli R, Shahnazari M, Oruji F, Fattahi S, Panahnejad E, et al. Evaluation of inflammasome activation in peripheral blood mononuclear cells of hemodialysis treated patients with glomerulonephritis. Iran J Pharm Res. 2021;20(3):609-17. doi: 10.22037/ijpr.2020.114260.14757.
  11. Wu Y, Hu Y, Wang B, Li S, Ma C, Liu X, et al. Dopamine uses the DRD5-ARRB2-PP2A signaling axis to block the TRAF6-mediated NF-κB pathway and suppress systemic inflammation. Mol Cell. 2020;78(1):42-56.e6. doi: 10.1016/j. molcel.2020.01.022.
  12. Gaweda G, Iyer RP, Shaver PR, Grilo GA, Dinkins ML, Stoffel HJ, et al. Dopamine receptor D3 agonist (pramipexole) reduces morphine-induced cardiac fibrosis. Biochem Biophys Res Commun. 2020;529(4):1080-5. doi: 10.1016/j. bbrc.2020.06.137.
  13. Mehralizadeh H, Nazari A, Oruji F, Roostaie M, Hosseininozari G, Yazdani O, et al. Cytokine sustained delivery for cancer therapy; special focus on stem cell- and biomaterial- based delivery methods. Pathol Res Pract. 2023;247:154528. doi: 10.1016/j.prp.2023.154528.
  14. Miller DR, Guenther DT, Maurer AP, Hansen CA, Zalesky A, Khoshbouei H. Dopamine transporter is a master regulator of dopaminergic neural network connectivity. J Neurosci. 2021;41(25):5453-70. doi: 10.1523/jneurosci.0223-21.2021.
  15. Reith ME, Kortagere S, Wiers CE, Sun H, Kurian MA, Galli A, et al. The dopamine transporter gene SLC6A3: multidisease risks. Mol Psychiatry. 2022;27(2):1031-46. doi: 10.1038/ s41380-021-01341-5.
  16. Salatino-Oliveira A, Rohde LA, Hutz MH. The dopamine transporter role in psychiatric phenotypes. Am J Med Genet B Neuropsychiatr Genet. 2018;177(2):211-31. doi: 10.1002/ ajmg.b.32578.
  17. Jabbarzadeh Kaboli P, Shabani S, Sharma S, Partovi Nasr M, Yamaguchi H, Hung MC. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671-85.
  18. Redina O, Babenko V, Smagin D, Kovalenko I, Galyamina A, Efimov V, et al. Gene expression changes in the ventral tegmental area of male mice with alternative social behavior experience in chronic agonistic interactions. Int J Mol Sci. 2020;21(18):6599. doi: 10.3390/ijms21186599.
  19. Amato D, Canneva F, Cumming P, Maschauer S, Groos D, Dahlmanns JK, et al. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry. 2020;25(9):2101-18. doi: 10.1038/s41380-018-0114-5.
  20. Lohoff FW, Bloch PJ, Hodge R, Nall AH, Ferraro TN, Kampman KM, et al. Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. Neurosci Lett. 2010;473(2):87-91. doi: 10.1016/j.neulet.2010.02.021.
  21. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A. 2006;103(12):4552-7. doi: 10.1073/ pnas.0504789103.
  22. Safarzadeh Kozani P, Shabani S. Adverse events and side effects of chimeric antigen receptor (CAR) T cell therapy in patients with hematologic malignancies. Trends Med Sci. 2021;1(1):e116301. doi: 10.5812/tms.116301.
  23. Hall FS, Chen Y, Resendiz-Gutierrez F. The streetlight effect: reappraising the study of addiction in light of the findings of genome-wide association studies. Brain Behav Evol. 2020;95(5):230-46. doi: 10.1159/000516169.
  24. Poisson CL, Engel L, Saunders BT. Dopamine circuit mechanisms of addiction-like behaviors. Front Neural Circuits. 2021;15:752420. doi: 10.3389/fncir.2021.752420.
  25. Guo G, Cai T, Guo R, Wang H, Harris KM. The dopamine transporter gene, a spectrum of most common risky behaviors, and the legal status of the behaviors. PLoS One. 2010;5(2):e9352. doi: 10.1371/journal.pone.0009352.
  26. Stolf AR, Szobot CM, Halpern R, Akutagava-Martins GC, Müller D, Guimaraes LS, et al. Crack cocaine users show differences in genotype frequencies of the 3’ UTR variable number of tandem repeats of the dopamine transporter gene (DAT1/SLC6A3). Neuropsychobiology. 2014;70(1):44-51. doi: 10.1159/000365992.
  27. Shabani S, Forouzandeh Moghadam M, Mousavi Gargari SL. Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method. Med Oncol. 2021;38(9):115. doi: 10.1007/s12032- 021-01561-3.
  28. Kim HN, Kim BH, Cho J, Ryu S, Shin H, Sung J, et al. Pathway analysis of genome-wide association datasets of personality traits. Genes Brain Behav. 2015;14(4):345-56. doi: 10.1111/ gbb.12212.
  29. Agabio R, Campesi I, Pisanu C, Gessa GL, Franconi F. Sex differences in substance use disorders: focus on side effects. Addict Biol. 2016;21(5):1030-42. doi: 10.1111/adb.12395.
Addiction & Health
Volume 17
Pages 1-5

Files

Share

How to cite

Statistics